Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL3795642 | 0.91 | PTGS1 (0.47) | PTGS1GSTK1DPP4DPP8DPP9 | |
| Sulfuric Acid SCHEMBL20787805 | 0.91 | PTGS1 (0.47) | PTGS1GSTK1DPP4DPP8DPP9 | |
| Sulfuric Acid SCHEMBL3798433 | 0.90 | PTGS1 (0.48) | PTGS1GSTK1DPP4DPP8DPP9 | |
| SCHEMBL30700928 | 0.85 | PTGS1 (0.52) | PTGS1GSTK1DPP4DPP8DPP9 | |
| Sulfuric Acid SCHEMBL7496979 | 0.83 | PTGS1 (0.65) | PTGS1GSTK1 | |
| Sulfuric Acid SCHEMBL7504984 | 0.83 | PTGS1 (0.65) | PTGS1GSTK1 | |
| SCHEMBL10490002 | 0.77 | PTGS1 (0.71) | PTGS1GSTK1 | |
| SCHEMBL6658547 | 0.77 | PTGS1 (0.57) | PTGS1GSTK1KMT2A | |
| SCHEMBL680549 | 0.77 | PTGS1 (0.71) | PTGS1GSTK1 | |
| SCHEMBL15333593 | 0.77 | PTGS1 (0.67) | PTGS1GSTK1DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3270889-B1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | MIRECA MEDICINES GMBH (DE) | 2024-02-07 | — | — | EP | claimed |
| EP-3395372-B1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | ENHANX BIOPHARM INC (TW) | 2022-04-06 | — | — | EP | claimed |
| US-10322087-B2 | Targeted liposomal delivery of cGMP analogues | MIRECA MEDICINES GMBH (DE) | 2019-06-18 | — | — | US | claimed |
| EP-2398500-B1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | 2 BBB MEDICINES B V (NL) | 2019-03-13 | — | — | EP | claimed |
| EP-3395372-A1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | 2-BBB Medicines B.V. (NL) | 2018-10-31 | — | — | EP | claimed |
| US-20180085311-A1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | MIRECA MEDICINES GMBH (DE) | 2018-03-29 | — | — | US | claimed |
| US-20140227185-A1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | TO-BBB HOLDING B.V. (NL) | 2014-08-14 | — | — | US | claimed |
| US-20110305751-A1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | TO-BBB HOLDING B.V. (NL) | 2011-12-15 | — | — | US | claimed |
| EP-3270889-B1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | MIRECA MEDICINES GMBH (DE) | 2024-02-07 | — | — | EP | disclosed |
| EP-3395372-B1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | ENHANX BIOPHARM INC (TW) | 2022-04-06 | — | — | EP | disclosed |
| US-10322087-B2 | Targeted liposomal delivery of cGMP analogues | MIRECA MEDICINES GMBH (DE) | 2019-06-18 | — | — | US | disclosed |
| EP-2398500-B1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | 2 BBB MEDICINES B V (NL) | 2019-03-13 | — | — | EP | disclosed |
| EP-3395372-A1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | 2-BBB Medicines B.V. (NL) | 2018-10-31 | — | — | EP | disclosed |
| US-20180085311-A1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | MIRECA MEDICINES GMBH (DE) | 2018-03-29 | — | — | US | disclosed |
| EP-3270889-A1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | Mireca Medicines GmbH (DE) | 2018-01-24 | — | — | EP | disclosed |
| WO-2016146669-A1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) | 2016-09-22 | — | — | WO | disclosed |
| US-20140227185-A1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | TO-BBB HOLDING B.V. (NL) | 2014-08-14 | — | — | US | disclosed |
| EP-2398500-A2 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | TO-BBB Holding B.V. (NL) | 2011-12-28 | — | — | EP | disclosed |
| US-20110305751-A1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | TO-BBB HOLDING B.V. (NL) | 2011-12-15 | — | — | US | disclosed |
| WO-2010095940-A2 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | TO-BBB HOLDING B.V. (NL) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10322087-B2 | Targeted liposomal delivery of cGMP analogues | PDE6C, PDE2A, GMPS | PTGS1 131/4885GSTK1 64/4885DPP4 2138/4885 |
| US-20110305751-A1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | GSS, GSTO1, SLC7A11 | PTGS1 292/4885GSTK1 13/4885DPP4 336/4885 |
| US-20180085311-A1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | PDE6C, PDE2A, GMPS | PTGS1 131/4885GSTK1 71/4885DPP4 2121/4885 |
| US-20140227185-A1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | GSS, GSTO1, SLC7A11 | PTGS1 292/4885GSTK1 13/4885DPP4 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.